AbCellera Biologics Inc.
ABCL· Nasdaq
Released Feb 21, 2023, after the close
10-K filed Feb 21, 2023, 52 days after period end · 0001564590-23-002128
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|
| Revenue | $21.54M | $139.31M | $207.91M |
| Net Income | -$29.89M | $59.95M | $117.00M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
AbCellera Biologics Inc. · CIK 1703057 · Engraved from SEC EDGAR